乳酸氨力农 | 75898-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 乳酸氨力农
• 中文别名: 3-羟基丙酸
• 英文名称: Inamrinone Lactate
• 英文别名: 3-amino-5-pyridin-4-yl-1H-pyridin-2-one;2-hydroxypropanoic acid
• CAS: 75898-90-7
• 化学式: C13H15N3O4
• 分子量: 277.28
• InChiKey: DOSIONJFGDSKCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.47
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Skin penetration system for salts of amine-functional drugs
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0351897A2

  公开（公告）日：1990-01-24

  The invention involves pharmaceutical compositions for topical application comprising: (a) a pharmaceutically-acceptable salt of addition of an amine-functional drug (other than opioid analgesic drugs); (b) a C₇ to C₂₂ straight-chain or branched-chain, saturated or unsaturated, fatty acid having a melting point of less than about 50°C; and (c) a C₃-C₄ alkane diol.

  本发明涉及用于局部应用的药物组合物，包括 (a) 一种胺功能药物（阿片类镇痛药除外）的药学上可接受的加成盐； (b) C₇ 至 C₂₂ 直链或支链、饱和或不饱和脂肪酸，熔点低于约 50°C；以及 (c) C₃-C₄ 烷二醇。
• Specific time-delayed burst profile delivery system
  申请人：Dexcel Pharma Technologies Ltd.

  公开号：EP1731142A1

  公开（公告）日：2006-12-13

  The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent; a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having substantially water insoluble hydrophilic particles embedded therein; and a first inner coating layer, comprising an agent that can cause the dissolution of at least one of the water insoluble components of the outer coating, and optionally a water soluble polymer, such that the insoluble particles in the outer coating, upon absorption of liquid, form channels leading to the inner coating layer, thus enabling the dissolution thereof, whereby the agents contained therein are released to cause the dissolution and/or degradation (destruction) of the outer coating, and the release of the pharmaceutically acceptable active agent from the core of the device.

  本发明提供了一种用于在胃肠道中延迟释放活性剂的给药装置，该装置包括一个内核，内核中含有活性剂；一个第一外涂层，外涂层中含有相对疏水的基本上不溶于水的聚合物，聚合物中嵌入了基本上不溶于水的亲水颗粒；第一内涂层层，包括可导致外涂层中至少一种水不溶成分溶解的药剂，以及可选的水溶性聚合物，从而使外涂层中的不溶性颗粒在吸收液体后形成通向内涂层层的通道，从而使其溶解，其中所含的药剂由此释放出来，导致外涂层溶解和/或降解（破坏），并从装置核心释放出药学上可接受的活性剂。
• Methods and systems of delivering medication via inhalation
  申请人：Next Safety, Inc.

  公开号：EP1911481A2

  公开（公告）日：2008-04-16

  Systems and methods for delivery of a drug to the respiratory system of a patient where the drug is supplied at a positive pressure relative to atmospheric pressure are provided. In particular, the drugs are delivered to the respiratory system of a patient who is capable of unassisted breathing. With the systems and methods of the present disclosure, medication available in a variety of forms is introduced in a controlled fashion into the air stream in aerosol, nebulized, or vaporized form.

  提供了向病人的呼吸系统输送药物的系统和方法，其中药物是在相对于大气压的正压下提供的。特别是，将药物输送到能够进行无助呼吸的患者的呼吸系统。利用本公开的系统和方法，可将各种形式的药物以气溶胶、雾化或汽化的形式有控制地引入气流中。
• Human EPO mimentic hinge core mimetibodies, compositions, methods and uses
  申请人：Centocor Ortho Biotech Inc.

  公开号：EP2123675A2

  公开（公告）日：2009-11-25

  The present invention relates to at least one novel human EPO mimetic hinge core mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one EPO mimetic hinge core mimetibody or specified portion or variant, EPO mimetic hinge core mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

  本发明涉及至少一种新型人EPO拟铰链核心拟态抗体或特定部分或变体，包括编码至少一种EPO拟铰链核心拟态抗体或特定部分或变体的分离核酸、EPO拟铰链核心拟态抗体或特定部分或变体、载体、宿主细胞、转基因动物或植物及其制造和使用方法，包括治疗组合物、方法和装置。
• Dual drug stent
  申请人：Cordis Corporation

  公开号：EP2246076A2

  公开（公告）日：2010-11-03

  Implantable medical devices may be utilized to locally delivery one or more drugs or therapeutic agents to treat a wide variety of conditions, including the treatment of the biological organism's reaction to the introduction of the implantable medical device. These therapeutic agents may be released under controlled and directional conditions so that the one or more therapeutic agents reach the correct target area, for example, the surrounding tissue and/or the bloodstream.

  植入式医疗器械可用于局部输送一种或多种药物或治疗剂，以治疗各种疾病，包括治疗生物机体对植入式医疗器械的反应。这些治疗剂可在受控和定向条件下释放，从而使一种或多种治疗剂到达正确的目标区域，例如周围组织和/或血液。